CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Abstract H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the
disialoganglioside GD2 (ref.). Chimeric antigen receptor-modified T cells targeting GD2 …
disialoganglioside GD2 (ref.). Chimeric antigen receptor-modified T cells targeting GD2 …
Cranioencephalic functional lymphoid units in glioblastoma
C Dobersalske, L Rauschenbach, Y Hua, C Berliner… - Nature medicine, 2024 - nature.com
The ecosystem of brain tumors is considered immunosuppressed, but our current
knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived …
knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived …
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Resistance to genotoxic therapies and tumor recurrence are hallmarks of glioblastoma
(GBM), an aggressive brain tumor. In this study, we investigated functional drivers of post …
(GBM), an aggressive brain tumor. In this study, we investigated functional drivers of post …
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma
G Pascual-Pasto, B McIntyre, MG Hines… - Nature …, 2024 - nature.com
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve
therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid …
therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid …
Clinical utility of a blood based assay for the detection of IDH1. R132H-mutant gliomas
Glioma represents the most common central nervous system neoplasm in adults. Current
classification scheme utilizes molecular alterations, particularly IDH1. R132H, to stratify …
classification scheme utilizes molecular alterations, particularly IDH1. R132H, to stratify …
Next-generation CAR T cell therapies for glioblastoma
Next-generation CAR T cell therapies for glioblastoma | Science Translational Medicine news
careers commentary Journals Science Science brought to you byGoogle Indexer Log in Become …
careers commentary Journals Science Science brought to you byGoogle Indexer Log in Become …
Integration of circadian rhythms and immunotherapy for enhanced precision in brain cancer treatment
M Quist, M van Os, LW van Laake, N Bovenschen… - …, 2024 - thelancet.com
Circadian rhythms significantly impact (patho) physiological processes, with disruptions
linked to neurodegenerative diseases and heightened cancer vulnerability. While …
linked to neurodegenerative diseases and heightened cancer vulnerability. While …
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
JN Brudno, MV Maus, CS Hinrichs - JAMA, 2024 - jamanetwork.com
Importance Chimeric antigen receptor (CAR) T cells are T lymphocytes that are genetically
engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and …
engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and …